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Abstract
Background: Advances in personalized medicine require the identification of variables that predict differential response to
treatments as well as the development and refinement of methods to transform predictive information into actionable
recommendations.
Objective: To illustrate and test a new method for integrating predictive information to aid in treatment selection, using
data from a randomized treatment comparison.
Method: Data from a trial of antidepressant medications (N = 104) versus cognitive behavioral therapy (N= 50) for Major
Depressive Disorder were used to produce predictions of post-treatment scores on the Hamilton Rating Scale for
Depression (HRSD) in each of the two treatments for each of the 154 patients. The patient’s own data were not used in the
models that yielded these predictions. Five pre-randomization variables that predicted differential response (marital status,
employment status, life events, comorbid personality disorder, and prior medication trials) were included in regression
models, permitting the calculation of each patient’s Personalized Advantage Index (PAI), in HRSD units.
Results: For 60% of the sample a clinically meaningful advantage (PAI$3) was predicted for one of the treatments, relative
to the other. When these patients were divided into those randomly assigned to their ‘‘Optimal’’ treatment versus those
assigned to their ‘‘Non-optimal’’ treatment, outcomes in the former group were superior (d = 0.58, 95% CI .17—1.01).
Conclusions: This approach to treatment selection, implemented in the context of two equally effective treatments, yielded
effects that, if obtained prospectively, would rival those routinely observed in comparisons of active versus control
treatments.
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Introduction
The call for an increased focus on ‘‘personalized medicine [1] ’’
is being met by efforts across medical fields to identify predictors of
treatment response [2]. In mental health, this includes recent
attempts to identify genetic [3–6] and neuroimaging [7–9] indices
that predict differential response to pharmacological interventions.
Variables from other domains (e.g., treatment history, course,
comorbidities) that predict differential response to pharmacologic
versus psychological treatments have also been identified [10–13].
Insofar as pretreatment patient characteristics predict differential
response to the interventions, patient outcomes can be optimized
by the systematic use of predictive information. Published reports
of prescriptive relationships tend to be limited to examinations of
single pre-treatment variables or of multiple variables that are each
considered in isolation. Clinicians are left with little guidance as to
how to combine such predictive information, especially in cases in
which the recommendations from multiple predictors conflict. As
Meehl and colleagues have observed, actuarial approaches are
preferred to clinical judgment in such cases [14], yet the potential
for actuarial methods to inform personalized medicine by making
prescriptive recommendations has not been realized.
In 1996, Barber and Muenz introduced a ‘‘matching method’’
to mental health researchers, with data from a randomized
comparison of two different psychotherapies, cognitive behavioral
therapy and interpersonal therapy. Utilizing three pre-treatment
variables (marital status, avoidant personality style, and obsessive
personality style), they calculated for each patient a score on a
‘‘matching factor [15].’’ On average, patients with positive
matching scores fared better in one of the two treatments, whereas
those with negative scores fared better in the other. Based on these
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findings, the authors recommended that clinicians consider these
variables when deciding which of these treatments to recommend
their patients. Their effort was a positive step towards personal-
izing treatment for depression, but neither their statistical
approach nor the clinical recommendations it generated has been
adopted by mental health researchers or practitioners.
In this paper we illustrate an approach to the use of predictive
information that builds upon Barber and Muenz’s efforts. The
methods we describe produce point predictions of symptom
severity at post-treatment for each individual in each of two
interventions. The comparison of the two estimates yields an
index, which we call the Personalized Advantage Index (PAI). The
PAI identifies the treatment predicted to produce the better
outcome for a given patient, and it provides the patient with a
quantitative estimate of the magnitude by which that treatment is
predicted to outperform the other. The utility of the approach is
then tested by comparing the outcomes of those who had been
randomly assigned to their indicated treatment versus those
assigned to their non-indicated treatment.
Methods
The approach we introduce and describe in this section of the
paper can be used in any context in which patients have been
randomized to two or more treatment conditions. For illustrative
purposes, we use data drawn from a randomized comparative trial
of cognitive behavioral therapy (CBT) versus the antidepressant
medication (ADM) paroxetine in the treatment of outpatients with
moderate to severe Major Depressive Disorder [16]. Each
treatment was provided for 16 weeks. The trial was conducted
at the University of Pennsylvania and Vanderbilt University
during the period 1996 to 2002. The sampling method and
outcomes have been described elsewhere [16,17]. The data are
hosted at the University of Pennsylvania. The protocol for the
study, titled ‘‘Cognitive Therapy and Pharmacotherapy in Major
Depression,’’ was approved by the respective institutional review
boards at the University of Pennsylvania, Philadelphia (Protocol
#034900), and Vanderbilt University, Nashville, Tennessee
(Protocol #7638). The data were de-identified before use in these
analyses. Following the approval of an appropriate request, the
data can be anonymized and provided to researchers. Written
consent was given by the patients for their information to be stored
in the university database and used for research.
To simplify the presentation of our approach, we focus on data
from the 154 patients for whom end-of-treatment scores were
available, in either CBT (N = 50 of 60 assigned) or ADM (N = 104
of 120 assigned). End-of-treatment scores were calculated as the
average of the final two scores (typically weeks 14 and 16) on the
primary outcome measure, the 17-item version of the clinician-
rated Hamilton Rating Scale for Depression (end-HRSD) [18].
The HRSD is the most commonly used assessment of depression
symptom severity in depression treatment outcome research. In
the present study, pre-treatment scores ranged from 20 to 36,
where scores of 20 to 22 indicate ‘‘moderate’’ severity and higher
scores indicate ‘‘severe’’ levels of depressive symptoms [19].
Differences of 3 or more points on the HRSD are considered to be
‘‘clinically significant [19].’’ In placebo-controlled randomized
trials, medications tend to result in HRSD scores that are 2 to 3
points lower than placebo, on average, over the typical 4–8 week
comparison period. This difference is associated with d-type effect
size estimates of approximately 0.3 to 0.4 [20].
The end-HRSD scores in this sample were not normally
distributed, which resulted in non-normal residuals when standard
regression models were calculated. A square root transformation of
end-HRSD resulted in distributions of raw scores and residuals
that did not differ from normality, allowing the use of the standard
linear regression models [21]. The values we report from the
models were squared so that they would be interpretable in terms
of the original HRSD scale.
Selection of the variables to include in the models
Nine variables were found to be either prognostic or prescriptive
in our sample. The details concerning these findings can be found
in three published works [10–12]. All nine variables were
measured prior to randomization. Four of these were prognostic
[22], in that they predicted end-HRSD scores irrespective of
treatment. These were: 1) pre-treatment HRSD, where higher
scores predicted higher end-HRSD scores; 2) Chronic versus Non-
chronic course of major depressive disorder, where chronicity was
associated with poorer outcome; 3) age, where older patients fared
more poorly [12]; and 4) low (,100), middle (.= 100 and ,115),
or high (.= 115) scores on the Shipley Institute of Living Scale, a
brief measure of intellectual functioning [23], where higher scores
predicted better outcomes.
The other five variables were identified as prescriptive in that they
predicted different outcomes depending on the treatment (ADM
versus CBT) that was received. These variables were detected as a
statistical interaction between that variable and treatment (ADM
versus CBT): 1) presence (favoring ADM) versus absence (favoring
CBT) of comorbid personality disorder [11]; 2) married or
cohabiting (favoring CBT) versus single; 3) employed or not
expected to work versus unemployed (favoring CBT); 4) number of
stressful life events (more events favoring CBT) [12]; 5) number of
prior antidepressant trials, capped at 2 trials (more trials favored
CBT) [10]. Like any prescriptive variable, these characteristics also
produced general effects on outcome, on average across treatments
[24]. The direction of these effects was as follows: being married,
employed, or having a higher number of life events predicted
lower end-HRSD scores, whereas having a personality disorder or
having had a larger number of prior medication attempts
predicted higher end-HRSD scores. Descriptive statistics for the
sample as a whole and for each treatment condition separately are
provided in Table 1 for each of the nine predictive variables.
There were no significant differences between ADM and CBT on
any of the variables (t-test for continuous variables, chi-square for
categorical variables; all p’s .0.1).
Generation of the predicted end-HRSD scores
We analyzed our data in MATLAB (The Mathworks Inc.,
Natick, MA). Using the GLMFIT procedure, we generated a
prediction of the end-HRSD score for each participant in each of
the two treatments. Hereafter we will refer to the prediction of the
end-HRSD score for the treatment the participant actually
received as the ‘‘factual prediction.’’ The ‘‘counterfactual predic-
tion’’ was the estimate of the participant’s end-HRSD score in the
treatment he or she did not receive. Both predictions were
generated by the same model, in which end-HRSD was the
dependent variable.
To generate these predictions, we used techniques employed in
leave-one-out cross-validation [25,26]. The leave-one-out procedure
(also known as a jackknife [27]) required the creation of 154 models,
each with a sample size of 153. Main effects for ‘‘Treatment’’ and
the prognostic and prescriptive variables, as well as terms
representing the interactions of Treatment and the prescriptive
variables, served as independent variables. For each of the 154
patients, the factual prediction was calculated by entering the
patient’s observed values on all of the independent variables into
the prediction model. All values were centered using Kraemer et
Making Personalized Treatment Recommendations
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al. ’s recommendations [24], whereby continuous measures were
mean-centered, and dummy code values for dichotomous
variables, including Treatment, were set at K and -K. We then
computed each patient’s counterfactual prediction by substituting
the value of the other treatment (eitherK or -K depending on the
patient’s actual assignment) in the Treatment main effect term, as
well as in all the terms representing the interactions of Treatment
and the prescriptive variables. Because each model is estimated
absent any information about the patient whose scores are to be
predicted, the predictions are considered to contain little or no bias
[25]. In essence, the accuracy of the set of predictions is what
would be expected if the procedure had been used to predict
outcomes in another set of patients who were drawn randomly
from the same population of patients, assuming they would be
assigned to the same treatments in the same way (i.e., randomly)
[27].
Properties of the predictions that will be examined
Using the predicted scores, we estimated: (1) the ‘‘true error’’ of
the factual predictions (i.e., the mean of the absolute value of the
difference between the observed scores and factual predictions); (2)
the standard error of the set of predictions; and (3) the magnitude
of the predicted difference, for each patient, of receiving the
treatment with the greater predicted benefit (Optimal) versus the
other (Non-optimal) treatment. This last value is an index of
‘‘predicted advantage’’ which we call the Personalized Advantage
Index (PAI). Because each individual is left out of the model from
which their end point values are predicted, and because the
Optimal treatment predicted for an individual is not tied to the
treatment actually received, we can take advantage of the initial
randomization of patients to treatments in order to test the utility
of the PAI by comparing the mean observed difference, in end-
HRSD units, between the set of patients who had been randomly
assigned to their Optimal treatment versus those who had been
assigned to their Non-Optimal treatment.
A worked example of the approach
Tables 2, 3, 4 illustrate how the procedure generated the
predictions for CBT and ADM, using one of the 154 patients from
the sample. This patient was selected because the PAI, the
observed end-HRSD, and the prediction error were near the
mean for the sample. Table 2 shows how this patient’s values on
two of the four prognostic variables (low intake HRSD; high
intellectual level) predicted better outcome (i.e., lower end-HRSD
scores, as indicated by negative values of a*b), whereas values on
the other two prognostic variables (older; chronic course) predicted
poorer outcome for this patient. As can be seen in the lower
portion of Table 2, the patient’s values on three of the prescriptive
variables (unmarried, unemployed, two prior ADM trials)
predicted poorer outcome irrespective of treatment. On two
others (three life stressors, no comorbid Personality Disorder), the
values of a*b are close to zero, indicating little influence on their
own in the prediction of outcome.
Table 3 shows how treatment affects the prediction of outcome,
both as a main effect and in interactions with each of the five
prescriptive variables. This patient’s values on three of the five
prescriptive variables indicated CBT as the Optimal Treatment
(unemployed, no comorbid Personality Disorder, two prior ADM
trials) as reflected in the negative b*c values. Values on the other
two variables indicated ADM as the Optimal Treatment
(unmarried, three life stressors), reflected in negative b*m values.
The model’s outputs (see Table 4) indicate that the patient’s
predicted end-HRSD is 13.0 in CBT and 18.6 in ADM. The
Personalized Advantage Index (PAI) for this individual is 5.6 in
favor of CBT; it represents the difference between the endpoint
scores predicted for each treatment.
Results
The true error of the end-HRSD score predictions (the average
absolute difference between the predicted and actual scores, across
the 154 patients) was 4.9. The standard error of prediction was
6.2. Figure 1 displays the distributions of the predicted end-HRSD
scores for the Optimal and Non-Optimal treatments across the
154 patients.
Table 1. Descriptive statistics for baseline variables.
Total (n = 154) ADM (n=104) CBT (n =50)
Role Variable Mean or % SD Mean or % SD Mean or % SD
Prognostic Intake-HRSD 23.8 3.2 23.8 3.2 23.7 3.4
Prognostic Chronic Subtype 55.2% — 58.7% — 48.0% —
Prognostic Age 40.3 11.3 40.0 11.2 40.9 11.6
Prognostic IQ
Lower IQ (IQ,100) 15.6% — 19.2% — 8.0% —
Mid IQ (100,= IQ,115) 52.6% — 52.9% — 52.0% —
Higher IQ (IQ.= 115) 31.8% — 27.9% — 40.0% —
Prescriptive Married 37.7% — 39.4% — 34.0% —
Prescriptive Employed 85.1% — 86.5% — 82.0% —
Prescriptive Comorbid Personality Disorder 48.1% — 51.0% — 42.0% —
Prescriptive Number Life Stressors Reported 6.6 4.8 6.7 5.1 6.3 4.3
Prescriptive Number Prior ADM Trialsa 0.7 0.8 0.7 0.8 0.8 0.8
ADM = Antidepressant Medication. CBT = Cognitive Behavioral Therapy. HRSD = Hamilton Rating Scale for Depression.
a = Capped at 2; sample breakdown for number prior medications: 0 = 52% (55% in ADM, 46% in CBT), 1 = 24% (21% in ADM, 30% in CBT), 2 or more = 24% (24% in
ADM, 24% in CBT).
doi:10.1371/journal.pone.0083875.t001
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The distribution of PAI scores is shown in Figure 2. The average
PAI was 4.2 (SD = 2.9), representing a 4.2 point difference in end-
HRSD scores between the Optimal treatment (predicted
mean = 7.4, SD = 3.0) versus the Non-Optimal treatment (pre-
dicted mean = 11.6; SD = 3.9). Note that a patient’s PAI can be as
low as 0, which would occur if the same outcome is predicted for
both treatments, irrespective of whether high or low end-HRSD
scores are predicted. As can be seen, whereas for some patients the
predicted advantage of being assigned to their Optimal treatment
was large, for others it was very small. For 62 (40%) of the patients,
the PAI did not meet the National Institute for Health and Care
Excellence (NICE) criterion (three points on the HRSD) for a
‘‘clinically significant’’ difference. For such patients, little weight
would be given to the model’s predictions in a treatment selection
decision; other factors (e.g., cost or patient preference) would likely
be used to guide treatment. We test our approach, therefore, using
the full sample of 154 patients as well as a reduced sample of those
92 patients (60%) whose PAI was ‘‘clinically significant.’’
The left side of Figure 3 shows, for the full sample, a comparison
of the average end-HRSD score for those assigned randomly to
their Optimal treatment versus those assigned to their Non-
Optimal treatment. Given that in 40% of the sample the Optimal
versus Non-Optimal difference was quite small, it is not surprising
that the observed difference between the Optimal and Non-
Optimal means in the full sample was relatively small; they differed
at the level of a nonsignificant trend (mean difference = 1.78;
pooled SD = 6.38; t = 1.73, 152, p = .09; d = .28, 95% confidence
interval 2.04 to .60). The right side of the figure gives the means
for the 60% of the sample for whom the predicted advantage of
the Optimal treatment was clinically significant. Here, the
observed mean difference was both clinically and statistically
significant (mean difference = 3.58; pooled SD = 6.12; t = 2.84,
90, p = .006; d = .58, 95% confidence interval .17 to 1.01).
Discussion
The method we have illustrated can be used to optimize
treatment selection in any context in which: a) more than one
intervention is under consideration, b) comparative outcome data
are available, and c) pre-treatment factors can be identified that
predict outcomes differentially across the interventions. In our
example, a randomized comparison of cognitive behavioral
Table 2. How the weights associated with prognostic and prescriptive variables combine with a patient’s values to contribute to
the calculation of the patient’s Personalized Advantage Index.
Variable Patient’s value Transformation Input value (a) Beta in LOO model (b) a*b
Intercept n/a n/a 1 3.15 3.15
Intake-HRSD (M= 23.8)a 20 Mean-centered 23.75 0.05 20.20
Age (M= 40.3)a 56 Mean-centered 15.67 0.01 0.20
IQ (Low, Middle, High)a High 21,0,1 1 20.18 20.18
Chronic Subtypea Yes 2.5, .5 0.5 0.39 0.19
Marital Statusb Unmarried 2.5, .5 20.5 20.45 0.22
Employment Statusb Unemployed 2.5, .5 20.5 20.50 0.25
Number Life Stressors Reported (M= 6.57)b 3 Mean-centered 20.65 20.07 0.04
Comorbid Personality Disorderb No 2.5, .5 20.5 0.17 20.08
Number Prior ADM Trials (capped at 2; M=0.72)b 2 Mean-centered 1.28 0.28 0.35
Total, for use in end-HRSD predictionsc Sum a*b 3.96
LOO = Leave One Out. ADM = Antidepressant Medication. HRSD = Hamilton Rating Scale for Depression.
a = Prognostic variable.
b = Prescriptive variable.
c = See Table 4.
doi:10.1371/journal.pone.0083875.t002
Table 3. The treatment (Tx) main effect and interactions of Tx with the prescriptive variables.
Tx=CBT Tx=ADM
Variable Beta in LOO model (b) Input (c) b*c Input (m) b*m
CBT (0.5) or ADM (20.5) 20.42 0.5 20.21 20.5 0.21
Tx*Marital Status 21.10 20.25 0.27 0.25 20.27
Tx*Employment Status 1.03 20.25 20.26 0.25 0.26
Tx*Life Stressors 20.35 20.32 0.11 0.32 20.11
Tx*Personality Disorder 0.66 20.25 20.16 0.25 0.16
Tx*Prior ADMs 20.17 0.64 20.11 20.64 0.11
Total, for use in end-HRSD predictionsa Sum b*c 20.35 Sum b*m 0.35
LOO = Leave One Out. CBT = Cognitive Behavioral Therapy. ADM = Antidepressant Medication. Tx = Treatment. HRSD = Hamilton Rating Scale for Depression.
a = See Table 4.
doi:10.1371/journal.pone.0083875.t003
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therapy versus medications for depression, the treatments
produced similar average levels of symptom reduction [16]. We
used our approach to predict, for each patient, which treatment
was more likely to lead to a better outcome. We then examined the
results of the natural experiment that occurred whereby some
patients had been randomized to their Optimal treatment and
some to their Non-optimal treatment. In line with our hypothesis,
patients randomized to their Optimal treatment tended to fare
better than those who were randomized to their Non-optimal
treatment.
When we restricted our test of the method to those for whom
the PAI was clinically significant, the advantage of assignment to
the Optimal treatment was, in effect size terms, approximately
twice the difference reported in a recent systematic review of
antidepressant drug versus placebo comparisons [28], and larger
than the average effect size observed between control and active
treatments utilized in general medical contexts [29]. This result
exemplifies an important feature of the approach: the ability to
identify individuals for whom the difference in outcome between
treatments is likely to be large, as well as those for whom the
predictions are similar and, thus, should not be given substantial
weight in a choice between the two treatments. In applications of
this approach, other factors, such as patient preference or
treatment costs would likely weigh heavily in treatment selection
decisions, when the PAI is small. It is important to emphasize that
both ADM and CBT are evidence-based treatments for depres-
sion. Thus, all patients, including those identified as having
received what for them was their Non-optimal treatment, received
what is considered, absent any contraindications, a valid and
appropriate treatment.
Although we could not conduct a prospective test with our data,
we approximated a critical feature of such a test by leaving each
patient’s data out of the model that was used to make predictions
for him or her. Thus, the benefits of treatment optimization we
observed should provide a good estimate of the advantage that
would have accrued to future patients from the same population
had the prediction algorithm been used to assign them to the same
treatments we studied. In a real world clinic, a consecutive series of
patients would be randomized to one of two evidence-based
treatments. Patient outcomes would be tracked, and baseline
characteristics would be used to generate the predictive algorithm
that would inform treatment decisions for future patients. The
weight given to each new patient’s treatment recommendation
would depend on the magnitude of the PAI generated by the
algorithm.
A true prospective test of our approach would begin with a
randomized trial of two interventions. A predictive model, as we
have described here, would be derived from the data obtained
during the randomized trial. The model would then be tested in
sample of patients who seek treatment in the same clinic in which
the randomized trial was performed, using the same treatments.
Outcomes of patients who are randomized to one of two
conditions would then be compared: (a) those whose treatment is
determined by random assignment, as in the first phase of the
study; versus (b) those whose assignment is determined by the
output of the predictive algorithm that was generated in the first
phase.
Table 4. How the estimates from Tables 2 and 3 combine to
produce a patient’s estimated end-HRSD scores in CBT and
ADM, respectively, and the PAI.
Tx=CBT Value Source Value Tx =ADM
3.96 ,—Sum a*b Table 2 Sum a*b—. 3.96
20.35 ,—Sum b*c Table 3 Sum b*m—. 0.35
3.6 Sum of sums 4.3
13.0 Predicted end-HRSDa 18.6
PAI = 5.6, favoring CBT
Tx = Treatment. CBT = Cognitive Behavioral Therapy. ADM = Antidepressant
Medication. HRSD = Hamilton Rating Scale for Depression. PAI = Personalized
Advantage Index; the difference between the predictions for CBT and ADM, in
end-HRSD units.
a = The square of the model output.
doi:10.1371/journal.pone.0083875.t004
Figure 1. Frequency histogram showing predicted end-HRSD scores for each patient in their Optimal and their Non-Optimal
treatment, as indicated by the treatment selection algorithm.
doi:10.1371/journal.pone.0083875.g001
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It is often challenging to identify prescriptive variables that will
replicate in a different population. Several features of the study
from which the present data were drawn likely contributed to the
strong prescriptive findings we obtained, and might also support a
successful effort to replicate them. Cognitive behavioral therapy
and antidepressant medications are both effective interventions for
depression, but they are very different methods of treatment that
likely work through different mechanisms [30]. We therefore
expected to be able to identify prescriptive variables, especially
given that several of the pre-treatment variables were included in
Figure 2. Frequency histogram showing Personalized Advantage Index (PAI) scores for all patients in the sample.
doi:10.1371/journal.pone.0083875.g002
Figure 3. Comparison of mean end-HRSD scores for patients randomly assigned to their Optimal treatment versus those assigned
to their Non-Optimal treatment. The left side gives the results for the full sample. The right side includes only patients for whom the algorithm
predicted a clinically significant advantage on the PAI of $3.
doi:10.1371/journal.pone.0083875.g003
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the intake battery precisely because prior research had suggested
that they predict differential response to these treatments. In
comparisons of two treatments that work through similar
mechanisms, such as might be true of two medications that
operate on similar neurotransmitter systems, the power of this
approach, or any approach that is contingent on the presence of
significant treatment-by-patient-characteristic interaction effects,
would likely be limited.
The variables in our example comprised information from
structured interviews, self-report questionnaires, and demographic
forms, any of which can readily be obtained in a routine clinical
setting. Other groups have begun to explore the potential of
genetics or neuroimaging to inform treatment decisions in
depressed patient populations [5,31–33]. In pharmacogenetic
and pharmacogenomic studies, perhaps because the interventions
included are mechanistically similar, the effects have thus far been
small [6]. In principle, however, information from multiple
different kinds of measures could be combined using the
procedures we describe above in order to provide more accurate
predictions than could be generated from any one predictor
considered in isolation.
The potential for neuroimaging-based treatment selection was
evidenced recently in an investigation by Mayberg and colleagues,
who explored the associations between pre-treatment brain
activation and outcomes in a randomized comparison of CBT
and ADM [32]. They reported that indexes of brain activity in six
regions, as assessed with positron emission tomography, were
associated with differential response to the two treatments. They
focused on their strongest finding, which was obtained from the
right anterior insula. Patients who remitted with CBT, as well as
those who did not remit with ADM, exhibited relatively low
activity in this region, whereas those who remitted in ADM, as
well as those who did not remit in CBT, exhibited relatively high
activity in that area. These findings represent a major contribution
to prediction of treatment response. However, they examined each
of the six indexes in isolation, and thus did not make maximal use
of the predictive information provided from the multiple brain
regions. Moreover, their approach does not allow for the
quantification of benefit from treatment matching. As we have
shown, some patients would be expected to derive comparable
benefits from either treatment, whereas for others there would be
little if any difference in outcomes expected between the two
treatments. Considering these factors, it is not clear how their
findings, or any set of findings in which multiple different
predictors are identified, would be used in clinical decision-
making on their own. Conversely, our approach produces a
clinically interpretable index of the size of the expected difference
in outcomes between the treatments. Future studies of neuroim-
aging or genetic markers as differential predictors of treatment
response would do well to include a wide variety of variables and
modalities in pre-treatment assessments and to take advantage of
the multivariate nature of the set of potential predictors [34–37].
Biostatisticians have described analytic frameworks to identify
prescriptive (moderator) variables [38,39], but less attention has
been paid to the development of procedures to translate
prescriptive findings into clear, actionable recommendations for
individual patients. We were alerted to the points of contact
between our approach and that of Barber and Muenz [15] while
we were developing and testing our method, at which time a
thorough review of the literature revealed no further developments
along these lines in the mental health field. Only after an extensive
review of the literature in other medical fields did we locate similar
efforts, in oncological medicine [40–42]. To our knowledge, none
of that prior work has been developed further or applied to the
differential prediction of individual patient outcomes.
The time is right for the revival, further development, and
application of these methods, first introduced 35 years ago [40], as
such approaches are suited perfectly to advance the goals of
personalized medicine. With the present effort we hope to inspire
renewed interest across medical fields in the development and
application of prescriptive algorithms that combine multiple
sources of information to yield estimates of patients’ outcomes in
more than one treatment. This approach promises to enhance
therapeutics by promoting the selection of the best treatment
among available options, with the additional feature that it
provides quantitative estimates of the benefits that can be expected
when such an algorithm is implemented.
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